Table 5.
Most Important Factor (Benefit or Harm) in Decision Making: Celecoxib
| All | F | M | HGD | No HGD | |
|---|---|---|---|---|---|
| All participants | |||||
| Number of subjects (N) | 100 | 28 | 72 | 45 | 55 |
| EAC | 18% | 14% | 19% | 27% | 11% |
| MI | 59% | 50% | 63% | 40% | 75% |
| Stroke | 19% | 32% | 14% | 27% | 13% |
| GI event | 3% | 4% | 3% | 7% | 2% |
| Among those willing to take celecoxib | |||||
| Number of subjects (N) | 15 | 4 | 11 | 9 | 6 |
| EAC | 100% | 100% | 100% | 100% | 100% |
| MI | 0 | 0 | 0 | 0 | 0 |
| Stroke | 0 | 0 | 0 | 0 | 0 |
| GI event | 0 | 0 | 0 | 0 | 0 |
| Among those unwilling to take celecoxib: | |||||
| Number of subjects (N) | 85 | 24 | 61 | 36 | 49 |
| EAC | 4% | 0 | 5% | 8% | 0 |
| MI | 69% | 58% | 74% | 50% | 90% |
| Stroke | 22% | 38% | 16% | 33% | 8% |
| GI event | 4% | 4% | 3% | 8% | 2% |
All = total group surveyed; HGD = history of high-grade dysplasia.
Percentages do not always add to 100% because of rounding.
EAC = esophageal adenocarcinoma; MI = myocardial infarction; GI event = ulcer or gastrointestinal bleeding.